These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23855261)

  • 1. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans.
    Nakamaru Y; Hayashi Y; Ikegawa R; Kinoshita S; Perez Madera B; Gunput D; Kawaguchi A; Davies M; Mair S; Yamazaki H; Kume T; Suzuki M
    Xenobiotica; 2014 Mar; 44(3):242-53. PubMed ID: 23855261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
    Nakamaru Y; Emoto C; Shimizu M; Yamazaki H
    Biopharm Drug Dispos; 2015 Apr; 36(3):148-62. PubMed ID: 25450725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.
    Halabi A; Maatouk H; Siegler KE; Faisst N; Hinrichsen H
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):290-6. PubMed ID: 27128835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
    Ceriello A; De Nigris V; Iijima H; Matsui T; Gouda M
    Drugs; 2019 May; 79(7):733-750. PubMed ID: 30982160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in rats using liquid chromatography-tandem mass spectrometry.
    Shantikumar S; Satheeshkumar N; Srinivas R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Oct; 1002():194-200. PubMed ID: 26340762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.
    Nakamaru Y; Hayashi Y; Sekine M; Kinoshita S; Thompson J; Kawaguchi A; Davies M; Jürgen Heuer H; Yamazaki H; Akimoto K
    Clin Ther; 2014 May; 36(5):760-9. PubMed ID: 24726088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a liquid chromatography/tandem-mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma.
    Park JW; Kim KA; Park JY
    Biomed Chromatogr; 2020 Feb; 34(2):e4721. PubMed ID: 31656058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
    Kim N; Patrick L; Mair S; Stevens L; Ford G; Birks V; Lee SH
    Xenobiotica; 2014 Jun; 44(6):522-30. PubMed ID: 24304170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review on Chemistry, Analysis and Pharmacology of Teneligliptin: A Novel DPP-4 Inhibitor.
    Sharma S; Sharma R; Hatware K; Patil K
    Mini Rev Med Chem; 2020; 20(12):1091-1100. PubMed ID: 32107992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans.
    Furuta S; Smart C; Hackett A; Benning R; Warrington S
    Xenobiotica; 2013 May; 43(5):432-42. PubMed ID: 23075005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
    Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
    Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults.
    Nakamaru Y; Hayashi Y; Davies M; Jürgen Heuer H; Hisanaga N; Akimoto K
    Clin Ther; 2015 Sep; 37(9):2007-18. PubMed ID: 26212570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
    Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
    Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teneligliptin for the treatment of type 2 diabetes.
    Goda M; Kadowaki T
    Drugs Today (Barc); 2013 Oct; 49(10):615-29. PubMed ID: 24191255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers.
    Kinoshita S; Kondo K
    Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):7-14. PubMed ID: 25424014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption, disposition and metabolic pathway of amiselimod (MT-1303) in healthy volunteers in a mass balance study.
    Kifuji T; Inoue S; Furukawa M; Perez Madera B; Goto T; Kumagai H; Mair SJ; Kawaguchi A
    Xenobiotica; 2019 Sep; 49(9):1033-1043. PubMed ID: 30231665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
    Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
    Vourvahis M; Gleave M; Nedderman AN; Hyland R; Gardner I; Howard M; Kempshall S; Collins C; LaBadie R
    Drug Metab Dispos; 2010 May; 38(5):789-800. PubMed ID: 20124396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
    He H; Tran P; Yin H; Smith H; Batard Y; Wang L; Einolf H; Gu H; Mangold JB; Fischer V; Howard D
    Drug Metab Dispos; 2009 Mar; 37(3):536-44. PubMed ID: 19074975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.
    Blech S; Ludwig-Schwellinger E; Gräfe-Mody EU; Withopf B; Wagner K
    Drug Metab Dispos; 2010 Apr; 38(4):667-78. PubMed ID: 20086031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.